Xenon Pharmaceuticals (NASDAQ:XENE) Trading 10.3% Higher

Share on StockTwits

Xenon Pharmaceuticals Inc (NASDAQ:XENE) was up 10.3% on Tuesday . The stock traded as high as $13.90 and last traded at $13.58, approximately 827,249 shares were traded during trading. An increase of 903% from the average daily volume of 82,498 shares. The stock had previously closed at $12.31.

A number of equities analysts have recently issued reports on the stock. ValuEngine cut shares of Xenon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 11th. Zacks Investment Research raised Xenon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research report on Saturday, October 26th. Finally, Guggenheim started coverage on Xenon Pharmaceuticals in a research report on Friday, September 20th. They issued a “buy” rating and a $25.00 target price for the company. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $17.67.

The company has a debt-to-equity ratio of 0.18, a current ratio of 8.25 and a quick ratio of 8.25. The company has a fifty day moving average price of $9.41 and a 200 day moving average price of $9.45. The stock has a market cap of $351.32 million, a P/E ratio of -10.21 and a beta of 1.43.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.16. The firm had revenue of $3.50 million during the quarter. As a group, sell-side analysts expect that Xenon Pharmaceuticals Inc will post -1.66 earnings per share for the current fiscal year.

In other Xenon Pharmaceuticals news, Director Frank A. Holler sold 7,600 shares of the firm’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $9.27, for a total value of $70,452.00. Following the transaction, the director now directly owns 124,161 shares of the company’s stock, valued at $1,150,972.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Simon N. Pimstone sold 10,395 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $9.51, for a total transaction of $98,856.45. Following the transaction, the chief executive officer now owns 258,122 shares of the company’s stock, valued at $2,454,740.22. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,087 shares of company stock worth $216,766. Corporate insiders own 8.35% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Altshuler Shaham Ltd boosted its stake in Xenon Pharmaceuticals by 4.3% during the 2nd quarter. Altshuler Shaham Ltd now owns 149,758 shares of the biopharmaceutical company’s stock valued at $1,477,000 after purchasing an additional 6,151 shares during the last quarter. NEA Management Company LLC purchased a new position in shares of Xenon Pharmaceuticals during the second quarter valued at approximately $1,802,000. Russell Investments Group Ltd. grew its holdings in Xenon Pharmaceuticals by 1,710.0% during the second quarter. Russell Investments Group Ltd. now owns 83,280 shares of the biopharmaceutical company’s stock worth $821,000 after buying an additional 78,679 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Xenon Pharmaceuticals during the second quarter worth $2,244,000. Finally, Renaissance Technologies LLC raised its position in Xenon Pharmaceuticals by 0.7% in the 2nd quarter. Renaissance Technologies LLC now owns 475,500 shares of the biopharmaceutical company’s stock valued at $4,688,000 after buying an additional 3,200 shares during the last quarter. Institutional investors own 62.24% of the company’s stock.

Xenon Pharmaceuticals Company Profile (NASDAQ:XENE)

Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.

Recommended Story: What is the Shanghai Stock Exchange Composite Index?

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.